Landmark Bio
This role is responsible for owning the strategy, design, and continuous improvement of the Quality Management System, ensuring it is phase-appropriate, scalable, and aligned with company growth. The position involves establishing quality policies, leading audit readiness programs, and managing supplier qualification and monitoring. Additionally, the role requires building and leading a high-performing Quality Systems team while fostering a strong culture of quality across the organization.
Landmark Bio is a cell and gene therapy manufacturing company that develops innovative technologies, products, and services to bridge the gap from bench to patient. They provide end-to-end support—process development, scale-up and GMP manufacturing, analytical testing, and regulatory-ready workflows—to translate research into clinical‑grade therapies. Focused on enabling academic groups and biotech partners, Landmark Bio offers scalable, compliant solutions and partnership models to accelerate commercialization and bring therapies to patients.
Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology
Jan 6, 2026
Artis expands its territory with acquisition of Landmark Bio for cell and gene manufacturing
Apr 2, 2025
Artis BioSolutions Emerges from Stealth, Acquires Landmark Bio
Apr 3, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Landmark Bio.
Landmark Bio didn’t post a salary, so this is our estimate from similar listings.
9% above the average for this role
New genetic medicine CDMO acquires Landmark Bio
Apr 2, 2025